Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 1
1968 1
1971 1
1974 1
1975 3
1976 3
1977 3
1978 3
1979 3
1980 3
1982 5
1983 8
1984 7
1985 9
1986 4
1987 7
1988 7
1989 8
1990 11
1991 12
1992 26
1993 18
1994 22
1995 33
1996 20
1997 40
1998 37
1999 39
2000 42
2001 47
2002 59
2003 69
2004 64
2005 75
2006 71
2007 73
2008 80
2009 74
2010 76
2011 86
2012 80
2013 90
2014 99
2015 99
2016 106
2017 114
2018 125
2019 141
2020 182
2021 224
2022 228
2023 248
2024 116

Text availability

Article attribute

Article type

Publication date

Search Results

2,620 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Dermatitis, atopic, 5"
Page 1
Biomarkers in atopic dermatitis.
Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Bakker D, et al. J Allergy Clin Immunol. 2023 May;151(5):1163-1168. doi: 10.1016/j.jaci.2023.01.019. Epub 2023 Feb 14. J Allergy Clin Immunol. 2023. PMID: 36792449 Free article. Review.
Atopic dermatitis (AD) is a complex and highly heterogeneous inflammatory skin disease. ...We have reviewed the use of different types of biomarkers as potential tools in the movement toward personalized medicine in AD, comprising different ways of endotyping patien …
Atopic dermatitis (AD) is a complex and highly heterogeneous inflammatory skin disease. ...We have reviewed the use of differe …
Epidemiology of adult atopic dermatitis.
Sacotte R, Silverberg JI. Sacotte R, et al. Clin Dermatol. 2018 Sep-Oct;36(5):595-605. doi: 10.1016/j.clindermatol.2018.05.007. Epub 2018 May 31. Clin Dermatol. 2018. PMID: 30217272 Review.
Atopic dermatitis (AD) is driven by a complex gene-environment interaction. Many of the risk factors and genetic underpinning previously observed for pediatric AD may not apply to adult atopic dermatitis, suggesting that these may largely be dif …
Atopic dermatitis (AD) is driven by a complex gene-environment interaction. Many of the risk factors and genetic underpinning …
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis.
[No authors listed] [No authors listed] Dermatology. 1993;186(1):23-31. doi: 10.1159/000247298. Dermatology. 1993. PMID: 8435513 Free article.
BACKGROUND: Assessment methods for atopic dermatitis (AD) are not standardized, and therapeutic studies are difficult to interpret. ...METHODS: Consensus definitions were given for items used in the scoring system (extent, intensity, subjective) and il …
BACKGROUND: Assessment methods for atopic dermatitis (AD) are not standardized, and therapeutic studies are difficult to inter …
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB, Lebwohl MG, Krueger JG. Guttman-Yassky E, et al. Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evaluated in AA patients. METHODS: Alopecia areata patients with and without concomitant atopic dermatitis were randomized 2:1 to r …
Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evalu …
Epidemiology of atopic dermatitis in adults: Results from an international survey.
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M, Eckert L. Barbarot S, et al. Allergy. 2018 Jun;73(6):1284-1293. doi: 10.1111/all.13401. Epub 2018 Feb 13. Allergy. 2018. PMID: 29319189
BACKGROUND: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). OBJECTIVE: To estimate the prevalence of AD in adults and by disease severity. ...RESULTS: Among participants by region, the point prevalence of adult AD in the overall/tr …
BACKGROUND: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). OBJECTIVE: To estimate the prev …
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Papp K, et al. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. J Am Acad Dermatol. 2021. PMID: 33957195 Free article. Clinical Trial.
METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients aged 12 years with AD for 2 years, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area. ...RESUL …
METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients …
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab-JP01 Study Group. Kabashima K, et al. N Engl J Med. 2020 Jul 9;383(2):141-150. doi: 10.1056/NEJMoa1917006. N Engl J Med. 2020. PMID: 32640132 Clinical Trial.
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic d …
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved …
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J, Wang J, Ong PY, Lio P, Gutierrez A, Capozza K, Martin SA, Frazier W, Wheeler K, Boguniewicz M, Spergel JM, Greenhawt M, Silverberg JI, Schneider L, Chu DK. Oykhman P, et al. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2657-2666.e8. doi: 10.1016/j.jaip.2022.06.044. Epub 2022 Jul 19. J Allergy Clin Immunol Pract. 2022. PMID: 35987995
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has conflicting views. ...RESULTS: Ten RCT (n = 599; baseline median of study mean age, 1.5 years; median of study mean SCOring Atopic …
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has …
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018 Sep;121(3):340-347. doi: 10.1016/j.anai.2018.07.006. Epub 2018 Jul 16. Ann Allergy Asthma Immunol. 2018. PMID: 30025911 Free article.
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is not well established. ...METHODS: A cross-sectional, population-based study of 602 adults was performed. Atopic dermatitis was …
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is n …
Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers.
He H, Olesen CM, Pavel AB, Clausen ML, Wu J, Estrada Y, Zhang N, Agner T, Guttman-Yassky E. He H, et al. Front Immunol. 2020 Aug 6;11:1768. doi: 10.3389/fimmu.2020.01768. eCollection 2020. Front Immunol. 2020. PMID: 32849633 Free PMC article.
Tape-stripping is a minimally invasive approach for skin sampling that captures the cutaneous immune/barrier abnormalities in atopic dermatitis (AD). However, tape-strips have not been used to evaluate molecular changes with therapeutic targeting. ...Significant dec …
Tape-stripping is a minimally invasive approach for skin sampling that captures the cutaneous immune/barrier abnormalities in atopic …
2,620 results